← Назад

Cleft lip/palate

ORPHA:199306Morphological anomalyMultigenic/multifactorialInfancy, Neonatal

Ассоциированные гены (13)

ARHGAP29
Rho GTPase activating protein 29
Major susceptibility factor in
OMIM: 610496
TP63
tumor protein p63
Major susceptibility factor in
OMIM: 603273
BMP4
bone morphogenetic protein 4
Major susceptibility factor in
OMIM: 112262
COBLL1
cordon-bleu WH2 repeat protein like 1
Major susceptibility factor in
OMIM: 610318
RIC1
RIC1 partner of RAB6A GEF complex
Major susceptibility factor in
OMIM: 610354
NECTIN1
nectin cell adhesion molecule 1
Major susceptibility factor in
OMIM: 600644
ARHGEF38
Rho guanine nucleotide exchange factor 38
Major susceptibility factor in
OMIM: 619919
CDH1
cadherin 1
Major susceptibility factor in
OMIM: 192090
IRF6
interferon regulatory factor 6
Major susceptibility factor in
OMIM: 607199
PDGFRA
platelet derived growth factor receptor alpha
Major susceptibility factor in
OMIM: 173490
MSX1
msh homeobox 1
Major susceptibility factor in
OMIM: 142983
DLG1
discs large MAGUK scaffold protein 1
Major susceptibility factor in
OMIM: 601014
DLX4
distal-less homeobox 4
Disease-causing germline mutation(s) in
OMIM: 601911

Фенотипы (21)

Очень частый (80–99%)1
HP:0006292Abnormality of dental eruption
Частый (30–79%)10
HP:0000175Cleft palate
HP:0000202Orofacial cleft
HP:0000220Velopharyngeal insufficiency
HP:0000403Recurrent otitis media
HP:0000750Delayed speech and language development
HP:0002033Poor suck
HP:0008872Feeding difficulties in infancy
HP:0009088Speech articulation difficulties
HP:0100334Unilateral cleft palate
HP:0200136Oral-pharyngeal dysphagia
Периодический (5–29%)9
HP:0000405Conductive hearing impairment
HP:0000689Dental malocclusion
HP:0001611Hypernasal speech
HP:0004395Malnutrition
HP:0006342Peg-shaped maxillary lateral incisors
HP:0010294Palate fistula
HP:0011044Abnormal number of permanent teeth
HP:0100337Bilateral cleft palate
HP:0200153Agenesis of lateral incisor
Очень редкий (1–4%)1
HP:0000327Hypoplasia of the maxilla

Эпидемиология (4)

Point prevalence
1-5 / 10 000
Europe
Prevalence at birth
1-5 / 10 000
United States
Prevalence at birth
6-9 / 10 000
France
Prevalence at birth
6-9 / 10 000
Worldwide

Лекарства и терапия

Источник: Open Targets Platform (в реальном времени)

Клинические исследования

Источник: ClinicalTrials.gov (в реальном времени)

Внешние ресурсы